---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000017"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:56:36.037557+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

## Summary
- ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
- 2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.
- Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.
- KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.
- Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years.

## SEC filing metadata
- accession: 0001730430-26-000017
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/0001730430-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000017
- JSON: https://secwatch.observer/filing/0001730430-26-000017.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000017.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported the quarter ended March 31, 2026 results: revenue $214.3 million, net income $22.6 million. Guidance raised.
  - Period: the quarter ended March 31, 2026
  - Revenue: $214.3 million
  - Net income: $22.6 million
  - Guidance: raised
  - Result: reported results
  source text: --- ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/0001730430-26-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.